• Explore /
  • Poster
  • / Systemic therapy and overall survival (OS) in patients (pts) with brain metastases from HER2-positive (HER2+) metastatic breast cancer (MBC).

Systemic therapy and overall survival (OS) in patients (pts) with brain metastases from HER2-positive (HER2+) metastatic breast cancer (MBC).

Abstract Poster

Authors

null

R. Bartsch

Department of Medicine 1, Clinical Division of Oncology, Medical University of Vienna, Vienna, Austria

R. Bartsch , A. Berghoff , U. Pluschnig , Z. Bago-Horvath , P. C. Dubsky , A. Rottenfusser , C. Wenzel , M. Rudas , F. Fitzal , K. Dieckmann , M. Gnant , C. Zielinski , G. G. Steger

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2011 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer - HER2/ER

Track

Breast Cancer

Sub Track

HER2+

Citation

J Clin Oncol 29: 2011 (suppl; abstr 597)

Abstract #

597

Poster Bd #

8G

Abstract Disclosures

Similar Posters

Poster

2015 ASCO Annual Meeting

ONT-380 in the treatment of HER2+ breast cancer central nervous system (CNS) metastases (mets).

ONT-380 in the treatment of HER2+ breast cancer central nervous system (CNS) metastases (mets).

First Author: Cristiano Ferrario

First Author: Diogo Bugano Diniz Gomes

First Author: Stefan Michiels

First Author: Rinat Yerushalmi